Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99449
Title:
Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.
Authors:
Sproston, Anthony R; Roberts, Stephen A; Davidson, Susan E; Hunter, Robin D; West, Catharine M L
Abstract:
A study was made of the prognostic value of measurements of pretreatment serum marker levels in patients with carcinoma of the uterine cervix undergoing radiotherapy. The markers studied were carcinoma antigen 125 (CA125), squamous cell carcinoma antigen (SCC) and tissue polypeptide antigen (TPA). The levels of all three markers increased with disease stage. In a univariate analysis stratifying patients according to either median values or cut-off levels representing the top of the normal range, pretreatment levels predicted patient survival (follow-up times 1-4 years). In a multivariate analysis, disease stage was the most important prognostic variable and, after allowing for stage, only CA125 was a significant independent predictor of treatment outcome. These data suggest that, in carcinoma of the cervix treated with radiotherapy, pretreatment measurements of CA125, but not SCC and TPA, may have a role to play in defining prognosis.
Affiliation:
Cancer Research Campaign Department of Experimental Radiation Oncology, Paterson Institute for Cancer Research, Manchester, UK.
Citation:
Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. 1995, 72 (6):1536-40 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Dec-1995
URI:
http://hdl.handle.net/10541/99449
PubMed ID:
8519673
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorSproston, Anthony Ren
dc.contributor.authorRoberts, Stephen Aen
dc.contributor.authorDavidson, Susan Een
dc.contributor.authorHunter, Robin Den
dc.contributor.authorWest, Catharine M Len
dc.date.accessioned2010-05-20T15:43:02Z-
dc.date.available2010-05-20T15:43:02Z-
dc.date.issued1995-12-
dc.identifier.citationSerum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy. 1995, 72 (6):1536-40 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid8519673-
dc.identifier.urihttp://hdl.handle.net/10541/99449-
dc.description.abstractA study was made of the prognostic value of measurements of pretreatment serum marker levels in patients with carcinoma of the uterine cervix undergoing radiotherapy. The markers studied were carcinoma antigen 125 (CA125), squamous cell carcinoma antigen (SCC) and tissue polypeptide antigen (TPA). The levels of all three markers increased with disease stage. In a univariate analysis stratifying patients according to either median values or cut-off levels representing the top of the normal range, pretreatment levels predicted patient survival (follow-up times 1-4 years). In a multivariate analysis, disease stage was the most important prognostic variable and, after allowing for stage, only CA125 was a significant independent predictor of treatment outcome. These data suggest that, in carcinoma of the cervix treated with radiotherapy, pretreatment measurements of CA125, but not SCC and TPA, may have a role to play in defining prognosis.en
dc.language.isoenen
dc.subjectBiological Tumour Markersen
dc.subjectCancer Antigensen
dc.subjectCancer Stagingen
dc.subjectUterine Cervical Canceren
dc.subject.meshAntigens, Neoplasm-
dc.subject.meshCA-125 Antigen-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPeptides-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshPrognosis-
dc.subject.meshSerpins-
dc.subject.meshTreatment Outcome-
dc.subject.meshTumor Markers, Biological-
dc.subject.meshUterine Cervical Neoplasms-
dc.titleSerum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.en
dc.typeArticleen
dc.contributor.departmentCancer Research Campaign Department of Experimental Radiation Oncology, Paterson Institute for Cancer Research, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.